Schechter Investment Advisors LLC Has $396,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

Schechter Investment Advisors LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 55.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,494 shares of the medical equipment provider’s stock after purchasing an additional 1,968 shares during the period. Schechter Investment Advisors LLC’s holdings in Hologic were worth $396,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. General Partner Inc. bought a new stake in shares of Hologic in the fourth quarter valued at about $26,000. Groupama Asset Managment raised its position in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. boosted its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of a number of research reports. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research note on Monday, February 3rd. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Raymond James reaffirmed an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Trading Down 0.4 %

Shares of Hologic stock opened at $62.08 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The business has a fifty day simple moving average of $68.77 and a two-hundred day simple moving average of $75.64. Hologic, Inc. has a 1 year low of $61.70 and a 1 year high of $84.67. The company has a market capitalization of $13.93 billion, a price-to-earnings ratio of 19.58, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.